The only in vitro experiment we had available on ivermectin used post-treatment 2 hours after infection, in Vero cells instead of pulmonary derived cell culture.
Later projections did not account for the long half life of the drug.
The increasingly likely possibility that SARS-CoV-2 arose from a systematic gain-of-function study on the emergence of human pathogens from wildlife reservoirs does not invalidate the implications of the study.
Along with the post-exposure prophylaxis trials, this further indicates genuine antiviral activity in vivo for ivermectin (not merely anti-inflammatory).
Denmark orders military to kill all mink in the country after mutated, mink-passaged SARS-CoV-2 strain with supposedly poor antibody response (details pending) spreads back to humans.
Extensive prior culling was unsuccessful in halting mink infections.
Terguride (5-HT2A/B antagonist) for prevention of PAH and ventricular or pulmonary fibrosis in conditions of acutely elevated plasma 5-HT @farid__jalali
There are various possible post-acute COVID-19 symptoms.
Cardiorespiratory functional capacity may sometimes take a few weeks to months to recover.
Patients who experienced extensive clotting may have longer-lasting damage to affected areas.
@Longco191 There may be a risk of developing an autoimmune or autoinflammatory condition, such as a new joint or connective tissue disorder, potentially requiring assessment by a rheumatologist for diagnosis and treatment. Anecdotally, this often does appear to be treatable to some extent.
@Longco191 Some acutely recovered patients have reported fairly strong indicators of developing POTS, which is usually symptomatically treatable with appropriate medication by e.g. GPs familiarized with the issue. The underlying cause is usually harder to address and may be neurological.